HC Wainwright Comments on OptiNose FY2029 Earnings

OptiNose, Inc. (NASDAQ:OPTN - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for OptiNose in a report released on Friday, January 3rd. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of $1.41 for the year. HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for OptiNose's current full-year earnings is ($0.20) per share.

Separately, Piper Sandler dropped their target price on shares of OptiNose from $45.00 to $15.00 and set an "overweight" rating for the company in a research report on Wednesday, November 13th.

OptiNose Stock Down 5.8 %

NASDAQ OPTN traded down $0.38 during trading hours on Monday, hitting $6.12. The company's stock had a trading volume of 30,392 shares, compared to its average volume of 42,064. OptiNose has a twelve month low of $4.82 and a twelve month high of $31.50. The firm has a market capitalization of $61.57 million, a P/E ratio of -21.86 and a beta of -0.15. The stock has a fifty day moving average of $7.69 and a 200 day moving average of $11.70.

Institutional Trading of OptiNose

A number of institutional investors and hedge funds have recently modified their holdings of OPTN. GSA Capital Partners LLP acquired a new position in OptiNose during the third quarter valued at approximately $61,000. XTX Topco Ltd bought a new stake in shares of OptiNose in the second quarter worth about $88,000. Squarepoint Ops LLC raised its position in shares of OptiNose by 173.7% during the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company's stock worth $178,000 after purchasing an additional 108,903 shares during the period. State Street Corp lifted its holdings in shares of OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company's stock valued at $229,000 after purchasing an additional 42,500 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in OptiNose by 15.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company's stock worth $764,000 after purchasing an additional 152,435 shares in the last quarter. 85.60% of the stock is owned by institutional investors.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.